Prognosis of Pancreatic Cancer Patients with Synchronous or Metachronous Malignancies from Other Organs Is Better than Those with Pancreatic Cancer Only

Su‐Jin Shin(Yonsei University), Seung‐Mo Hong(Ulsan College), Dae Wook Hwang(Asan Medical Center), Kyu‐pyo Kim(Ulsan College), Hosub Park(Asan Medical Center), Baek‐Yeol Ryoo(Asan Medical Center), Song Cheol Kim(Ulsan College), Changhoon Yoo(Ulsan College), Sang Soo Lee(Chungbuk National University Hospital), Dong‐Wan Seo(Ulsan College), Jin‐hong Park, You‐Na Sung(Korea University)
Cancer Research and Treatment
December 20, 2017
10.4143/crt.2017.494
Cited by 30

Related Papers

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
|Science|2008|4k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1.1k
Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers
|Proceedings of the National Academy of Sciences|2017|577